Human Epidermal Growth Factor Receptor 2 (HER2) in Advanced Gastric Cancer: Current Knowledge and Future Perspectives
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Human Epidermal Growth Factor Receptor 2 (HER2) in Advanced Gastric Cancer: Current Knowledge and Future Perspectives
Authors
Keywords
-
Journal
DRUGS
Volume 80, Issue 4, Pages 401-415
Publisher
Springer Science and Business Media LLC
Online
2020-02-19
DOI
10.1007/s40265-020-01272-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Multicenter phase II study of trastuzumab with S-1 plus oxaliplatin for chemotherapy-naïve, HER2-positive advanced gastric cancer
- (2019) Daisuke Takahari et al. Gastric Cancer
- Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer
- (2019) Taroh Satoh et al. Gastric Cancer
- First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma.
- (2019) Yelena Yuriy Janjigian et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study.
- (2019) Josep Tabernero et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study
- (2019) Kohei Shitara et al. LANCET ONCOLOGY
- Circulating Tumor DNA Sequencing Analysis of Gastroesophageal Adenocarcinoma
- (2019) Steven B. Maron et al. CLINICAL CANCER RESEARCH
- HER-family ligands promote acquired resistance to trastuzumab in gastric cancer
- (2019) Aïda Sampera et al. MOLECULAR CANCER THERAPEUTICS
- HER2 heterogeneity is a poor prognosticator for HER2-positive gastric cancer
- (2019) Akio Kaito et al. World Journal of Clinical Cases
- Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
- (2019) Shanu Modi et al. NEW ENGLAND JOURNAL OF MEDICINE
- miR-200c inhibits TGF-β-induced-EMT to restore trastuzumab sensitivity by targeting ZEB1 and ZEB2 in gastric cancer
- (2018) Xinliang Zhou et al. CANCER GENE THERAPY
- Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFNγ secretion
- (2018) Bharat K.R. Chaganty et al. CANCER LETTERS
- Antitumor activity of pan-HER inhibitors in HER2-positive gastric cancer
- (2018) Takahiro Yoshioka et al. CANCER SCIENCE
- HER2 testing of gastro-oesophageal adenocarcinoma: a commentary and guidance document from the Association of Clinical Pathologists Molecular Pathology and Diagnostics Committee
- (2018) Newton A C S Wong et al. JOURNAL OF CLINICAL PATHOLOGY
- Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer
- (2018) Takeru Wakatsuki et al. JOURNAL OF GASTROENTEROLOGY
- Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
- (2018) Kohei Shitara et al. LANCET
- Dual silencing of EGFR and HER2 enhances the sensitivity of gastric cancer cells to gefitinib
- (2018) Liying Wang et al. MOLECULAR CARCINOGENESIS
- The HER4-YAP1 axis promotes trastuzumab resistance in HER2-positive gastric cancer by inducing epithelial and mesenchymal transition
- (2018) Jiaolong Shi et al. ONCOGENE
- Role of circulating tumor DNA in the management of patients with colorectal cancer
- (2018) Emilie Moati et al. Clinics and Research in Hepatology and Gastroenterology
- Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300
- (2018) Y -J Bang et al. ANNALS OF ONCOLOGY
- Phase II clinical trial of second-line weekly paclitaxel plus trastuzumab for patients with HER2-positive metastatic gastric cancer
- (2018) Yosuke Horita et al. ANTI-CANCER DRUGS
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Single agent activity of ZW25, a HER2-targeted bispecific antibody, in heavily pretreated HER2-expressing cancers.
- (2018) Funda Meric-Bernstam et al. JOURNAL OF CLINICAL ONCOLOGY
- A randomized phase II study of weekly paclitaxel ± trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum: WJOG7112G (T-ACT).
- (2018) Akitaka Makiyama et al. JOURNAL OF CLINICAL ONCOLOGY
- Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study
- (2018) Josep Tabernero et al. LANCET ONCOLOGY
- Immunotherapy in advanced gastric cancer, is it the future?
- (2018) C. Coutzac et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: Results of GASTric cancer HER2 reassessment study 3 (GASTHER3).
- (2017) Seyoung Seo et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II study of trastuzumab with irinotecan in HER2-positive metastatic or advanced gastric cancer patients previously treated with trastuzumab and failed: HGCSG 1201/OGSG1205.
- (2017) Yasuyuki Kawamoto et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab beyond first progression in cases of HER2-positive advanced gastric or gastro-esophageal junction cancer: Initial results from KSCC1105, a trastuzumab observational cohort study.
- (2017) Akitaka Makiyama et al. JOURNAL OF CLINICAL ONCOLOGY
- HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology
- (2017) Angela N. Bartley et al. JOURNAL OF CLINICAL ONCOLOGY
- HELOISE: Phase IIIb Randomized Multicenter Study Comparing Standard-of-Care and Higher-Dose Trastuzumab Regimens Combined With Chemotherapy as First-Line Therapy in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
- (2017) Manish A. Shah et al. JOURNAL OF CLINICAL ONCOLOGY
- Pharmacokinetics, Biodistribution, and Radiation Dosimetry for89Zr-Trastuzumab in Patients with Esophagogastric Cancer
- (2017) Joseph A. O'Donoghue et al. JOURNAL OF NUCLEAR MEDICINE
- Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Yoon-Koo Kang et al. LANCET
- Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study
- (2017) Peter C Thuss-Patience et al. LANCET ONCOLOGY
- Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
- (2017) Gunter von Minckwitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Detection of HER2 Amplification in Circulating Tumor Cells of HER2-Negative Gastric Cancer Patients
- (2017) Yuji Mishima et al. Targeted Oncology
- Trastuzumab in Combination with FOLFIRI in Patients with Advanced HER2-Positive Gastro-Esophageal Adenocarcinoma: A Retrospective Multicenter AGEO Study
- (2017) Aziz Zaanan et al. Targeted Oncology
- The clinicopathological parameters and prognostic significance of HER2 expression in gastric cancer patients: a meta-analysis of literature
- (2017) Yu-ying Lei et al. World Journal of Surgical Oncology
- Correlation between human epidermal growth factor receptor 2 expression level and efficacy of trastuzumab beyond progression in metastatic gastric cancer
- (2017) Yukiya Narita et al. Oncology Letters
- Trastuzumab beyond progression in patients with HER2-positive advanced gastric adenocarcinoma: a multicenter AGEO study
- (2017) Juliette Palle et al. Oncotarget
- Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
- (2016) E. C. Smyth et al. ANNALS OF ONCOLOGY
- 3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
- (2016) F. Cardoso et al. ANNALS OF ONCOLOGY
- Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial
- (2016) Jifang Gong et al. BMC CANCER
- DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1
- (2016) Y. Ogitani et al. CLINICAL CANCER RESEARCH
- Phase II study of the effectiveness and safety of trastuzumab and paclitaxel for taxane- and trastuzumab-naïve patients with HER2-positive, previously treated, advanced, or recurrent gastric cancer (JFMC45-1102)
- (2016) Kazuhiro Nishikawa et al. INTERNATIONAL JOURNAL OF CANCER
- HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research
- (2016) F. Pietrantonio et al. INTERNATIONAL JOURNAL OF CANCER
- A phase II trial of trastuzumab combined with irinotecan in patients with advanced HER2-positive chemo-refractory gastric cancer: OGSG1203 (HERBIS-5).
- (2016) Kazuhiro Nishikawa et al. JOURNAL OF CLINICAL ONCOLOGY
- Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2–Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC—A Randomized Phase III Trial
- (2016) J. Randolph Hecht et al. JOURNAL OF CLINICAL ONCOLOGY
- Involvement of microRNAs in HER2 signaling and trastuzumab treatment
- (2016) Ling Mao et al. TUMOR BIOLOGY
- Preclinical evidence of multiple mechanisms underlying trastuzumab resistance in gastric cancer
- (2016) Chiara Arienti et al. Oncotarget
- Droplet digital PCR measurement of HER2 in patients with gastric cancer
- (2015) H Kinugasa et al. BRITISH JOURNAL OF CANCER
- Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: A retrospective study
- (2015) Émilie Soularue et al. BULLETIN DU CANCER
- Optimal Patient Selection for Trastuzumab Treatment in HER2-Positive Advanced Gastric Cancer
- (2015) C.-Y. Ock et al. CLINICAL CANCER RESEARCH
- Phase II trial of dacomitinib in patients with HER2-positive gastric cancer
- (2015) Do-Youn Oh et al. Gastric Cancer
- Serum HER2 extracellular domain as a potential alternative for tissue HER2 status in metastatic gastric cancer patients
- (2014) Zhi Peng et al. Biomarkers in Medicine
- Src, a potential target for overcoming trastuzumab resistance in HER2-positive breast carcinoma
- (2014) G Peiró et al. BRITISH JOURNAL OF CANCER
- Preexisting oncogenic events impact trastuzumab sensitivity in ERBB2-amplified gastroesophageal adenocarcinoma
- (2014) Jihun Kim et al. JOURNAL OF CLINICAL INVESTIGATION
- Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment ofHER2-Amplified Advanced Gastric Cancer in Asian Populations: TyTAN—A Randomized, Phase III Study
- (2014) Taroh Satoh et al. JOURNAL OF CLINICAL ONCOLOGY
- Circulating Tumor Cells (CTCs) Detected by RT-PCR and Its Prognostic Role in Gastric Cancer: A Meta-Analysis of Published Literature
- (2014) Shuyi Wang et al. PLoS One
- Role of epithelial-mesenchymal transition in gastric cancer initiation and progression
- (2014) Zhao Peng WORLD JOURNAL OF GASTROENTEROLOGY
- Level ofHER2Gene Amplification Predicts Response and Overall Survival in HER2-Positive Advanced Gastric Cancer Treated With Trastuzumab
- (2013) Carlos Gomez-Martin et al. JOURNAL OF CLINICAL ONCOLOGY
- Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab – a translational project in the neoadjuvant GeparQuinto trial
- (2012) I Witzel et al. BRITISH JOURNAL OF CANCER
- Human epidermal growth factor receptor 2 (HER2) extracellular domain levels are associated with progression-free survival in patients with HER2-positive metastatic breast cancer receiving lapatinib monotherapy
- (2011) Allan Lipton et al. CANCER
- Intratumoral Heterogeneity Determines Discordant Results of Diagnostic Tests for Human Epidermal Growth Factor Receptor (HER) 2 in Gastric Cancer Specimens
- (2011) Jiyuan Yang et al. CELL BIOCHEMISTRY AND BIOPHYSICS
- Human epidermal growth factor receptor 2 testing in gastric carcinoma: issues related to heterogeneity in biopsies and resections*
- (2011) Stephen Lee et al. HISTOPATHOLOGY
- Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways
- (2011) Siyuan Zhang et al. NATURE MEDICINE
- Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase
- (2011) J. T. Garrett et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target
- (2008) C. Gravalos et al. ANNALS OF ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started